Eam Global Investors LLC Tricida, Inc. Transaction History

Eam Global Investors LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $223,268 - $356,809	-26,236 Reduced 18.44%	116,056 $1.22 Million
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $1.04 Million - $1.69 Million	142,292 New	142,292 $1.38 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.